Amoxicillin
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Amoxicillin
- Pharmacist Assessment Report
- Amoxicillin: beta-lactam antibiotic (inhibits bacterial cell wall synthesis) → polyclonal hyperviscosity syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amoxicillin: beta-lactam antibiotic (inhibits bacterial cell wall synthesis) → polyclonal hyperviscosity syndrome
One-Sentence Summary
Amoxicillin is a beta-lactam antibiotic that acts against susceptible bacteria. The TxGNN model predicts it may be relevant to polyclonal hyperviscosity syndrome, but no clinical trials and no publications in the data compiled for this report support this prediction, so it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Amoxicillin belongs to the beta-lactam class of antibiotics, which inhibit bacterial cell wall synthesis.
Polyclonal hyperviscosity syndrome is driven by excess immunoglobulins in the blood and has no antibacterial target. No plausible mechanistic link between amoxicillin and this condition was identified. The high score is a model prediction only and is not supported by any trial or publication. At this stage the prediction should be regarded as unsubstantiated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11947T | AMILOXYN | Capsule 500 mg (as trihydrate) | Not recorded in the local data |
Safety Considerations
Contraindications and key warnings text was not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for label safety information.
Drug Interactions (100 interacting drugs were recorded; selected examples):
- Major: Methotrexate; live cholera vaccine (Vibrio cholerae CVD 103-HgR strain)
- Moderate: Doxycycline, minocycline, demeclocycline, ethinylestradiol, estradiol, anisindione, dicoumarol, mycophenolate mofetil, entecavir, balsalazide
- Minor: Allopurinol, amiloride, azithromycin, clarithromycin, erythromycin
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (evidence level L5). There are no supporting trials or publications and no plausible mechanistic link between a beta-lactam antibiotic and a condition of immunoglobulin-driven hyperviscosity.
To proceed, the following is needed:
- A credible mechanistic hypothesis linking amoxicillin to polyclonal hyperviscosity syndrome
- Any preclinical or clinical data directly studying this disease
- Product Information (PI) review for warnings and contraindications
- Detailed mechanism of action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.